Long-term oxygen therapy (LTOT), the provision of oxygen for continuous use at home for patients with chronic hypoxemia, is regarded by clinicians as an essential component of the management of severe chronic obstructive pulmonary disease (COPD). [1] [2] [3] It is the only treatment, other than stopping smoking 4 that has been clearly proven to alter outcome in COPD. [1] [2] [3] The evidence that LTOT improves survival comes from two landmark clinical trials in patients with severe COPD and chronic hypoxemia (PaO 2 at or below 7.3 kPa [55 mmHg]) published nearly 30 years ago.
The UK Medical Research Council (MRC) trial 2 randomized 87 patients to 15 h of supplemental oxygen therapy or no oxygen, whereas the US Nocturnal Oxygen Therapy Trial (NOTT) 3 randomized 203 patients to 24 h of oxygen or to 12 h of oxygen therapy. In the MRC study, 3-year mortality with oxygen was 45% compared to 67% without oxygen 2 ; in the NOTT study, 19-month mortality was almost halved in the continuous oxygen group when compared to the 12-h oxygen group. 3 Pooling the results demonstrated a dose-response effect with greatest survival for patients in the 24-h oxygen group (NOTT), then the 15-h group (MRC), followed by the 12-h group (NOTT), with the worst survival in the group who did not receive oxygen (MRC control group). 2, 3 Although there are no studies demonstrating improved survival with LTOT in other chronic respiratory diseases associated with chronic hypoxemia, in clinical practice, the results from the MRC and NOTT studies are extrapolated to other patient groups, and LTOT is offered to the majority of patients with chronic hypoxemia, including patients with interstitial lung disease 5 and cystic fibrosis. 6 LTOT is usually recommended for at least 15 h daily, including overnight, as chronic hypoxemia worsens during sleep. In many countries, including the UK, LTOT is delivered in the home by nasal cannulae, with oxygen supplied by an oxygen concentrator, rather than by oxygen cylinders. However, patients often have difficulty achieving the recommended 15 h of LTOT; of 930 patients with COPD on LTOT in France, only 45% used 15 h or more 7 , and in a study of 176 patients in London, only 61% used 16 h or more. 8 From the clinician's perspective, starting a patient on LTOT requires explanation of the reasons for recommending oxygen and teaching a patient how to use the equipment appropriately and safely. However, for the patient, there are also physical, psychological, and emotional implications of starting to use oxygen. These are important to identify as it is well-recognized that understanding and addressing patient beliefs and concerns about their treatment is an important way to improve adherence. 9, 10 This includes clinicians explicitly addressing the common belief that many patients (and some health professionals) have that oxygen is being provided as a treatment for breathlessness. At the outset, clinicians need to communicate clearly that there is no evidence that LTOT improves breathlessness and that it is not being recommended as a treatment for their breathlessness, rather as an evidence-based treatment to improve survival. There is also increasing evidence that shared agendas, including shared treatment aims, between clinicians and patients improve selfmanagement in long-term conditions. 11, 12 The article by Cullen and Stiffler 13 therefore provides much needed data on the experiences of patients using LTOT. The authors use data from four qualitative studies, mostly in patients with COPD, to identify the common themes from patients' experiences of using LTOT. Because of the shortage of published qualitative studies on patients' experiences of using oxygen, the patient groups analyzed in this article are heterogeneous, which means their experiences may vary. Patients prescribed oxygen for breathlessness, but who are not hypoxemic, are likely to have different health beliefs about oxygen therapy than those who have been prescribed oxygen, having been identified by their clinician as chronically hypoxemic and patients using transtracheal oxygen, which is rarely provided now, may have a different experience to that of patients using nasal cannulae. 13 Despite this limitation, clinicians who look after patients on LTOT will clearly recognize the two main findings in this article 13 from discussions with their own patients. The first finding is that patients do rationalize their oxygen use in the context of how much it interferes with their lifestyle and restricts them. Patient patterns of oxygen use reflect their own health beliefs and are developed by trial and error into a pattern that works best for that particular individual. Secondly, and perhaps even more importantly, the loss of control and dependency that is felt by patients using LTOT conflicts with a patient's desire for self-mastery and to be able to care for one's self. Unfortunately, it was not possible in the study to separate out the impact of treatment with oxygen from the impact of the underlying disease; patients with COPD who are not on LTOT also have to negotiate lifestyle interference and physical restriction and deal with the conflict between dependency and self-management. It is, therefore, difficult to know how much the findings in the study reflect the experience of having severe COPD and how much they reflect the experience of using LTOT. 13 The results of the study by Cullen and Stiffler 13 are important and relevant to clinicians providing care for patients on LTOT. They remind us that we need to explore the health beliefs and concerns of patients starting LTOT to help them find a pattern of oxygen use that works for them as an individual, yet delivers the survival benefits we, as clinicians, want for our patients. This is also a timely study for clinicians involved in developing models of healthcare for patients with long-term conditions, in particular, where the principles of partnership working with patients are being used to support self-management, for example, the Health Foundation's co-creating health project in the UK. 14 Recognizing, and helping patients to manage, the conflict between being in control of their lives and the dependency that patients on LTOT feel is likely to be central in developing effective healthcare for patients with hypoxemic chronic respiratory disease.
The article by Cullen and Stiffler 13 enables us to reflect on how we can improve the experience of patients who we are recommending use LTOT to improve their survival. Aligning the clinician and patient agenda, by increasing clinician awareness of patient concerns, may increase adherence to oxygen therapy and hence improve outcome in severe COPD. Furthermore, even though a treatment is lifesaving, clinicians have a responsibility to make a patient's experience of treatment as acceptable as possible to that individual. Finally, this study demonstrates that we need more high quality research to increase our understanding of our patients' perspectives of having chronic respiratory disease.
